243 related articles for article (PubMed ID: 17003289)
1. Actions of glucagon-like peptide-1 on KATP channel-dependent and -independent effects of glucose, sulphonylureas and nateglinide.
McClenaghan NH; Flatt PR; Ball AJ
J Endocrinol; 2006 Sep; 190(3):889-96. PubMed ID: 17003289
[TBL] [Abstract][Full Text] [Related]
2. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.
Duffy NA; Green BD; Irwin N; Gault VA; McKillop AM; O'Harte FP; Flatt PR
Eur J Pharmacol; 2007 Jul; 568(1-3):278-86. PubMed ID: 17573070
[TBL] [Abstract][Full Text] [Related]
3. Interaction of nateglinide with K(ATP) channel in beta-cells underlies its unique insulinotropic action.
Hu S
Eur J Pharmacol; 2002 May; 442(1-2):163-71. PubMed ID: 12020694
[TBL] [Abstract][Full Text] [Related]
4. Nateglinide stimulates glucagon-like peptide-1 release by human intestinal L cells via a K(ATP) channel-independent mechanism.
Kitahara Y; Miura K; Yasuda R; Kawanabe H; Ogawa S; Eto Y
Biol Pharm Bull; 2011; 34(5):671-6. PubMed ID: 21532155
[TBL] [Abstract][Full Text] [Related]
5. Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum.
Shigeto M; Katsura M; Matsuda M; Ohkuma S; Kaku K
J Pharmacol Exp Ther; 2007 Jul; 322(1):1-7. PubMed ID: 17409272
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.
Hu S; Wang S; Fanelli B; Bell PA; Dunning BE; Geisse S; Schmitz R; Boettcher BR
J Pharmacol Exp Ther; 2000 May; 293(2):444-52. PubMed ID: 10773014
[TBL] [Abstract][Full Text] [Related]
7. Nateglinide, but not repaglinide, stimulates growth hormone release in rat pituitary cells by inhibition of K channels and stimulation of cyclic AMP-dependent exocytosis.
Gromada J; Bokvist K; Høy M; Olsen HL; Lindström P; Hansen BS; Gotfredsen CF; Rorsman P; Thomsen MK
Eur J Endocrinol; 2002 Jul; 147(1):133-42. PubMed ID: 12088930
[TBL] [Abstract][Full Text] [Related]
8. A role of PLC/PKC-dependent pathway in GLP-1-stimulated insulin secretion.
Shigeto M; Cha CY; Rorsman P; Kaku K
J Mol Med (Berl); 2017 Apr; 95(4):361-368. PubMed ID: 28097390
[TBL] [Abstract][Full Text] [Related]
9. Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1.
de Heer J; Holst JJ
Diabetes; 2007 Feb; 56(2):438-43. PubMed ID: 17259389
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin and insulin secretion due to common mechanisms by a new hypoglycemic agent, A-4166, in perfused rat pancreas.
Fujitani S; Ikenoue T; Akiyoshi M; Maki T; Yada T
Metabolism; 1996 Feb; 45(2):184-9. PubMed ID: 8596487
[TBL] [Abstract][Full Text] [Related]
11. Alterations of insulin secretion following long-term manipulation of ATP-sensitive potassium channels by diazoxide and nateglinide.
Ball AJ; Flatt PR; McClenaghan NH
Biochem Pharmacol; 2005 Jan; 69(1):59-63. PubMed ID: 15588714
[TBL] [Abstract][Full Text] [Related]
12. The mechanisms underlying the unique pharmacodynamics of nateglinide.
Hu S; Boettcher BR; Dunning BE
Diabetologia; 2003 Mar; 46 Suppl 1():M37-43. PubMed ID: 12652357
[TBL] [Abstract][Full Text] [Related]
13. Effects of sulphonylureas and diazoxide on insulin secretion and nucleotide-sensitive channels in an insulin-secreting cell line.
Sturgess NC; Kozlowski RZ; Carrington CA; Hales CN; Ashford ML
Br J Pharmacol; 1988 Sep; 95(1):83-94. PubMed ID: 3146398
[TBL] [Abstract][Full Text] [Related]
14. Cav1.2 and Cav1.3 are differentially coupled to glucagon-like peptide-1 potentiation of glucose-stimulated insulin secretion in the pancreatic beta-cell line INS-1.
Jacobo SM; Guerra ML; Hockerman GH
J Pharmacol Exp Ther; 2009 Nov; 331(2):724-32. PubMed ID: 19710366
[TBL] [Abstract][Full Text] [Related]
15. Glucose triggers protein kinase A-dependent insulin secretion in mouse pancreatic islets through activation of the K+ATP channel-dependent pathway.
Thams P; Anwar MR; Capito K
Eur J Endocrinol; 2005 Apr; 152(4):671-7. PubMed ID: 15817925
[TBL] [Abstract][Full Text] [Related]
16. Acute and long-term effects of nateglinide on insulin secretory pathways.
Ball AJ; Flatt PR; McClenaghan NH
Br J Pharmacol; 2004 May; 142(2):367-73. PubMed ID: 15155541
[TBL] [Abstract][Full Text] [Related]
17. Glucose-dependent and glucose-sensitizing insulinotropic effect of nateglinide: comparison to sulfonylureas and repaglinide.
Hu S; Wang S; Dunning BE
Int J Exp Diabetes Res; 2001; 2(1):63-72. PubMed ID: 12369728
[TBL] [Abstract][Full Text] [Related]
18. Selectivity of prandial glucose regulators: nateglinide, but not repaglinide, accelerates exocytosis in rat pancreatic A-cells.
Bokvist K; Hoy M; Buschard K; Holst JJ; Thomsen MK; Gromada J
Eur J Pharmacol; 1999 Dec; 386(1):105-11. PubMed ID: 10611470
[TBL] [Abstract][Full Text] [Related]
19. Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166).
Ikenoue T; Akiyoshi M; Fujitani S; Okazaki K; Kondo N; Maki T
Br J Pharmacol; 1997 Jan; 120(1):137-45. PubMed ID: 9117089
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism.
Light PE; Manning Fox JE; Riedel MJ; Wheeler MB
Mol Endocrinol; 2002 Sep; 16(9):2135-44. PubMed ID: 12198249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
